Morepen Laboratories Ltd

Morepen Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Morepen Laboratories Ltd

₹ 66.6 -1.87%
23 May - close price
morepen.com BSE: 500288 NSE: MOREPENLAB
About

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]

Key Points

Market Leadership
The company is a leader in the pharmaceutical and medical devices industry, holding the top position in 6 APIs with the following market shares as of H1 FY25:
Montelukast (anti-asthmatic): 70%
Loratadine (anti-allergy): 69%
Desloratadine (anti-allergy): 49%
Fexofenadine (anti-allergy): 31%
Atorvastatin (cholesterol reducer): 20%
Rosuvastatin (cholesterol reducer): 19%
Additionally, it is a leader in other products including Sitagliptin, Linagliptin, Dapagliflozin, etc. [1] [2]

Website BSE NSE
  • Market Cap ₹ 3,649 Cr.
  • Current Price ₹ 66.6
  • High / Low ₹ 101 / 41.7
  • Stock P/E 35.9
  • Book Value ₹ 21.6
  • Dividend Yield 0.00 %
  • ROCE 13.2 %
  • ROE 9.81 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 3.09 times its book value
  • Company has a low return on equity of 10.1% over last 3 years.
  • Dividend payout has been low at 3.60% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
342 274 383 345 337 369 381 395 393 386 384 403 382
323 261 356 323 321 344 352 344 336 337 341 372 352
Operating Profit 19 14 27 21 15 25 30 51 56 49 43 32 30
OPM % 6% 5% 7% 6% 4% 7% 8% 13% 14% 13% 11% 8% 8%
3 1 1 1 3 2 3 4 4 3 5 5 3
Interest 1 0 0 1 1 0 0 2 1 1 1 1 4
Depreciation 5 4 4 5 5 5 5 6 7 4 4 5 12
Profit before tax 17 10 23 18 13 22 27 47 53 47 43 30 17
Tax % 14% 28% 28% 28% 21% 27% 27% 25% 24% 26% 26% 25% 31%
14 7 17 13 10 16 20 35 40 35 32 23 12
EPS in Rs 0.30 0.14 0.32 0.25 0.20 0.31 0.39 0.69 0.78 0.69 0.58 0.41 0.22
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
336 370 452 548 561 717 792 1,112 1,449 1,339 1,538 1,555
290 324 388 487 501 652 728 1,000 1,320 1,262 1,376 1,401
Operating Profit 46 47 64 60 60 65 64 112 129 77 162 153
OPM % 14% 13% 14% 11% 11% 9% 8% 10% 9% 6% 11% 10%
4 1 -3 4 4 4 9 12 10 6 13 16
Interest 10 9 10 7 4 2 2 2 -7 2 4 7
Depreciation 46 39 35 34 33 38 34 28 21 18 22 24
Profit before tax -6 1 16 23 26 29 37 94 126 63 149 138
Tax % 0% 19% -1% 0% 0% 0% 14% 0% 20% 27% 26% 26%
-6 1 16 23 26 29 32 94 101 46 111 102
EPS in Rs -0.14 0.01 0.35 0.52 0.58 0.64 0.72 2.10 2.11 0.90 2.17 1.85
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 11%
Compounded Sales Growth
10 Years: 15%
5 Years: 14%
3 Years: 2%
TTM: 1%
Compounded Profit Growth
10 Years: 68%
5 Years: 26%
3 Years: 0%
TTM: -8%
Stock Price CAGR
10 Years: 18%
5 Years: 33%
3 Years: 19%
1 Year: 36%
Return on Equity
10 Years: 13%
5 Years: 13%
3 Years: 10%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 90 90 90 90 90 90 90 90 96 102 102 110
Reserves 115 103 119 134 161 188 217 355 503 678 787 1,072
209 200 186 168 134 139 142 17 19 25 28 96
95 106 139 155 206 203 212 385 417 300 362 444
Total Liabilities 508 500 535 548 591 619 662 848 1,033 1,106 1,279 1,721
289 244 216 191 182 153 135 144 156 171 217 366
CWIP 0 0 0 0 0 0 0 2 14 17 24 28
Investments 118 118 118 118 118 118 119 119 118 118 126 205
100 138 201 239 291 349 408 583 745 800 912 1,122
Total Assets 508 500 535 548 591 619 662 848 1,033 1,106 1,279 1,721

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
33 51 50 49 61 15 11 49 -69 -102 77 29
-1 -30 -27 -15 -24 -10 -12 -69 -23 -36 -84 -280
-29 -20 -28 -31 -38 -0 5 47 66 144 0 260
Net Cash Flow 3 1 -5 3 -1 4 3 28 -25 6 -6 9

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 44 48 65 55 72 62 56 51 56 70 75 69
Inventory Days 60 56 53 68 79 71 93 84 95 85 85 107
Days Payable 122 124 140 126 176 123 111 95 80 86 103 127
Cash Conversion Cycle -18 -21 -22 -3 -25 10 38 40 71 69 57 50
Working Capital Days -16 -16 -6 -91 -66 -31 -4 22 62 111 110 155
ROCE % 0% 2% 8% 8% 8% 8% 9% 21% 22% 9% 18% 13%

Shareholding Pattern

Numbers in percentages

6 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
36.74% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 35.66% 35.66% 35.66%
0.95% 1.15% 0.89% 0.96% 1.00% 1.29% 2.11% 1.85% 1.67% 2.08% 2.22% 1.94%
4.08% 3.98% 3.74% 2.93% 2.32% 2.27% 2.21% 2.15% 2.14% 1.69% 1.64% 1.67%
0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
58.24% 56.63% 57.15% 57.88% 58.45% 58.20% 57.46% 57.76% 57.96% 60.57% 60.46% 60.72%
No. of Shareholders 2,87,1152,90,3673,06,0303,06,1503,01,8323,04,0013,04,2893,36,0193,48,7664,30,9294,48,3614,68,860

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls